Spotlight on Renin

Skeggs LT , Kahn JR , Lentz KE , Shumway NP Preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 1957;106:439-53.

Flather MD , Yusuf S. , Kober L. et al. Long-term ACEinhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. ACE inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-81.

ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998;97:2202-12.

Lee VC , Rhew DC , Dylan M. , Badamgarav E. , Braunstein GD , Weingarten SR Meta analysis: angiotensin receptor blockers in chronic heart failure and high risk acute myocardial analysis: angiotensin receptor blockers in chronic heart failure and high risk acute myocardial infarction. Ann Intern Med 2004;141:693-704.

Lewis EJ , Hunsicker LG , Bain RP , Rohde RD The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.

Lewis EJ , Hunsicker LG , Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.

Brenner BM , Cooper ME , de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.

The GISEN Group. Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy . Lancet 1997;349:1857-63.

Yusuf S. , Sleight P. , Pogue J. , Bosch J. , Davies R. , Dagenais G. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:45-53.

Navar GL , Harrison-Bernard LM , Imig JD , Mitchell KD Renal actions of angiotensin II and AT1 receptors. In: Angiotensin II Receptor Antagonists, edited by Epstein M , Brunner HR , Philadelphia , Hanley & Belfus, 2001, pp. 190.

Fisher NDL , Hollenberg NK Renin Inhibition: What are the Therapeutic Opportunties. J Am Soc Nephrol 2005;16:592-9.

Fisher NDL , Hollenberg NK Is there a future for renin inhibitors? Expert Opin Investig Drugs 2001;10:417-26.

Ondetti MA Design of specific inhibitors of angiotensin converting enzyme: New class of orally active antihypertensive agents. Science 1977;196:441-4.

Kleinert HD , Stein HH Specific renin inhibitors: Concepts and prospects . In: Hypertension, Pathophysiology, Diagnosis and Management, Vol. 2: Laragh JH , Brenner BM (eds), New York, Raven Press ;1995,pp.3065-77.

Nussberger J. , Wuerzner G. , Jensen C. , Brunner HR Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100) . Comparison with

enalapril. Hypertension 2002;39:e1-e8. 16. Stanton A. , Jensen C. , Nussberger J. , O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003;42:1-7.

Skinner SL The pathophysiology of prorenin. In: The ReninAngiotensin System , edited by Ian J , Robertson S , Nicholls MG , New York, Gower Medical Publishing ; 1993, pp.7.1-11.

Luetscher JA , Kraemer FB , Wilson DM Prorenin and vascular complications of diabetes . Am J Hypertens 1989;2:382-6.

Yoshida H. A study on inactive renin in the plasma of patients with diabetes mellitus . Hokkaido Igaku Zasshi. Hokkaido J Med Sci 1989;64:232-42.

Franken AAM , Derkx FHM , Man in't Veld AJ etal. High plasma prorenin in diabetes mellitus and its correlation with some complications . J Clin EndocrinolMetab 1990;71: 1008-15.

Wilson D. , Luetscher JA Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus. N Engl J Med 1990;323:1101-06.

Danser AHJ , van den Dorpel MA , Deinum J. et al. Renin, prorenin and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endcrinol Metab 1989;68:160-7.

Deinum J. , Derkx FHM , Danser AHJ , Schalekamp Madh. Identification and quantification of renin and prorenin in the bovine eye . Endocrinology 1990;126:1673-82.

Derkx FHM. Human prorenin [Thesis], Rotterdam, Erasmus University of Rotterdam, 1987.

Misbin I. , Grant MB , Pecker MS , Atlas SA Elevated levels of plasma prorenin (inactive renin) in diabetic and nondiabetic patients with autonomic dysfunction. J Clin Endocrinol Metab 1987;64:964-8.

Wood JM , Stanton JL , Hofbauer KG Inhibitors of renin as potential therapeutic agents. J Enzyme Inhib 1987;1:169-85.

Nguyen G. , Delarue F. , Berrou J. , Rondeau E. , Sraer JD Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int 1996;50:1897-903.

Neutel JM , Luther RR , Boger RS , Weber MA Immediate blood pressure effects of the renin inhibitor enalkiren and the ACE inhibitor enalaprilat. Am Heart J 1991 ;122:1094-100.

Kiowski W. , Linder L. , Kleinbloesem C. , Van Brummelen P. , Buhler FR Blood pressure control of the renin-angiotensin system in normotensive subjects . Circulation 2002;85:1-8.

Fisher NDL , Allan D. , Kifor I. , Gaboury CL , Williams GH , Moore TJ , Hollenberg NK Responses to converting enzyme and renin inhibition: Role of angiotensin II in humans . Hypertension 1994;23:44-51.

Fisher NDL , Hollenberg NK Renal vascular responses to renin inhibition with zankiren in men. Clin Pharmacol Ther 1995;57:342-8.